Previous 10 | Next 10 |
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights -- RADR®, Lantern's proprietary A.I. and machine learning platform, grew from 1.2 billion to over 18 billion data points, enhancing its precision, insights, and capabilit...
Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 PR Newswire DALLAS , March 3, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RAD...
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio - Lantern Pharma's A.I. and machine learning platform, RADR®, aided in the...
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, ...
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System - Designations reinforce unmet need for treatment o...
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors Lantern Pharma Announces Collaboration & Research Agreement with The Danish C...
Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284 Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - A...
Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference PR Newswire DALLAS , Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intellige...
Lantern Pharma (NASDAQ:LTRN) announces positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting. The study demonstrated LP-284's broad in vitro anti-tumor activity in lymphoma, multiple myeloma, and leukemia cells. Not...
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting - LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells - LP-284 exhibited potency in lymphoma, ...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...